Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Vignette Bio in the transaction, and Cooley represented Candid Therapeutics. Candid Therapeutics, a biotechnology company, acquired Vignette Bio...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented JenaValve Technology in the transaction. Involved fees earner: Heather Aune – Gunderson Dettmer Stough Villeneuve Franklin & Hachigian;...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Element Biosciences in the transaction. Element Biosciences Inc., developer of pioneering technologies to empower science, announced it raised...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Xaira Therapeutics in the transaction. Xaira Therapeutics (Xaira), an AI biotechnology company, from formation and through $1 billion...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Archetype AI in the transaction. Archetype AI, a physical AI company, announced its $13 million Seed financing led...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian represented Contineum Therapeutics in the offering, and Sidley Austin represented the underwriters. Contineum Therapeutics, a clinical stage biopharmaceutical company,...
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer Stough Villeneuve Franklin & Hachigian advised Natera, and Davis Polk & Wardwell advised the representatives of the several underwriters on the offering. Natera, Inc....
You must be a Standard 1 Year member to access this content.
Gunderson Dettmer represented Pipeline Therapeutics on the deal. Pipeline Therapeutics, a clinical-stage biopharmaceutical company, entered into a global license and development agreement with Janssen Pharmaceutica NV...
You must be a Standard 1 Year member to access this content.
